search
Back to results

Evaluation of Vitamin D Requirements During Pregnancy

Primary Purpose

Vitamin D Deficiency

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
cholecalciferol (vitamin D3)
cholecalciferol
Sponsored by
Medical University of South Carolina
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Vitamin D Deficiency focused on measuring vitamin D, cholecalciferol, pregnancy, bone mineral density

Eligibility Criteria

16 Years - 45 Years (Child, Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria: Women who are within the ages of 16-45 years In good general health Less than 12 weeks pregnant (based on last menstrual period) Exclusion Criteria: Mothers with preexisting type I or type II diabetes Mothers with preexisting hypertension Mothers with preexisting parathyroid disease or uncontrolled thyroid disease Mothers with multiple fetuses (e.g., twins, triplets, etc.)

Sites / Locations

  • Medical University of South Carolina

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Experimental

Experimental

Arm Label

cholecalciferol-400 IU

cholecalciferol 2000 IU

cholecalciferol 4000 IU

Arm Description

Control group receiving 400 IU/day plus 0 IU vitamin D3 as placebo/day

Experimental group receiving 2000 IU total vitamin D3/day.

Experimental group receiving 4000 IU/day cholecalciferol

Outcomes

Primary Outcome Measures

25-Hydroxyvitamin D Concentration
Circulating total 25(OH)D concentration measured in serum at visit 7, one month prior to delivery

Secondary Outcome Measures

Full Information

First Posted
February 15, 2006
Last Updated
August 9, 2016
Sponsor
Medical University of South Carolina
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
search

1. Study Identification

Unique Protocol Identification Number
NCT00292591
Brief Title
Evaluation of Vitamin D Requirements During Pregnancy
Official Title
Evaluation of Vitamin D Requirements During Pregnancy
Study Type
Interventional

2. Study Status

Record Verification Date
August 2016
Overall Recruitment Status
Completed
Study Start Date
January 2004 (undefined)
Primary Completion Date
January 2010 (Actual)
Study Completion Date
January 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Medical University of South Carolina
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to determine the effectiveness of vitamin D supplementation during pregnancy starting at the beginning of the second trimester. Mothers will be randomized to one of three vitamin D dosing groups: 400, 2,000 or 4,000 international units per day. It is hypothesized that the highest dosing regimen will result in a better vitamin D status of women regardless of their ethnicity or race.
Detailed Description
The prevalence of hypovitaminosis D in reproductive aged African-American women occurs at a rate of > 40%. Two factors have contributed to this public health problem: an inadequate DRI for vitamin D and avoidance of sun exposure/use of sunscreen. This startling rate of hypovitaminosis D requires that the DRI for vitamin D in pregnancy be evaluated in a detailed manner. The Cochrane Library (2002) released a report stating that there is insufficient data to evaluate the effects of vitamin D supplementation during pregnancy. Recently, the safety of prolonged supplementation with up to 25x's DRI (10,000 IU/day) was demonstrated in nonpregnant adults. It is essential to determine what dose of vitamin D is required to eliminate hypovitaminosis D during pregnancy and provide the fetus/neonate with adequate vitamin D stores during development and growth, particularly in darkly pigmented individuals. The aim of this research proposal, then, is to determine the efficacy, effectiveness, and safety of maternal vitamin D supplementation (as a function of ethnicity and UV exposure) in the prevention of hypovitaminosis D in the pregnant mother and her fetus/neonate. We hypothesize that darkly pigmented mothers will require substantially higher oral supplementation with vitamin D to eliminate hypovitaminosis D as compared to their Caucasian counterparts. We propose a comprehensive clinical trial to test our hypothesis. Mothers at 12 weeks' gestation will be randomized to one of three vitamin D treatment groups: Control, 400-, 2,000-, or 4,000 IU/day to be continued throughout pregnancy. Calcium and vitamin D homeostasis and skeletal remodeling in the mother will be monitored closely throughout the pregnancy. Bone density of the mother will be measured at 12 weeks' gestation and one-month postpartum. Follow-up growth and skeletal integrity assessments of the infant will be performed at birth, 1, 6 and 12 months stratified by infant feeding regime. Through these proposed studies, the prevalence of hypovitaminosis D among mothers, their developing fetuses and neonates, and the utility of maternal therapeutic intervention with vitamin D for both mother and fetus/infant will be assessed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vitamin D Deficiency
Keywords
vitamin D, cholecalciferol, pregnancy, bone mineral density

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
501 (Actual)

8. Arms, Groups, and Interventions

Arm Title
cholecalciferol-400 IU
Arm Type
Active Comparator
Arm Description
Control group receiving 400 IU/day plus 0 IU vitamin D3 as placebo/day
Arm Title
cholecalciferol 2000 IU
Arm Type
Experimental
Arm Description
Experimental group receiving 2000 IU total vitamin D3/day.
Arm Title
cholecalciferol 4000 IU
Arm Type
Experimental
Arm Description
Experimental group receiving 4000 IU/day cholecalciferol
Intervention Type
Drug
Intervention Name(s)
cholecalciferol (vitamin D3)
Intervention Description
randomized control trial of three vitamin D doses: 400, 2000 and 4000 IU/day
Intervention Type
Drug
Intervention Name(s)
cholecalciferol
Other Intervention Name(s)
vitamin D3
Intervention Description
comparing vitamin D requirements of pregnant women and their fetuses from 12 weeks' gestation through pregnancy
Primary Outcome Measure Information:
Title
25-Hydroxyvitamin D Concentration
Description
Circulating total 25(OH)D concentration measured in serum at visit 7, one month prior to delivery
Time Frame
7 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Women who are within the ages of 16-45 years In good general health Less than 12 weeks pregnant (based on last menstrual period) Exclusion Criteria: Mothers with preexisting type I or type II diabetes Mothers with preexisting hypertension Mothers with preexisting parathyroid disease or uncontrolled thyroid disease Mothers with multiple fetuses (e.g., twins, triplets, etc.)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bruce W. Hollis, Ph.D.
Organizational Affiliation
Medical University of South Carolina
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Carol L. Wagner, M.D.
Organizational Affiliation
Medical University of South Carolina
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Donna Johnson, M.D.
Organizational Affiliation
Medical University of South Carolina
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Thomas C. Hulsey, Sc.D.
Organizational Affiliation
Medical University of South Carolina
Official's Role
Study Chair
Facility Information:
Facility Name
Medical University of South Carolina
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
15671234
Citation
Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr. 2005 Feb;135(2):317-22. doi: 10.1093/jn/135.2.317.
Results Reference
background
PubMed Identifier
15689596
Citation
Hollis BW, Wagner CL. Normal serum vitamin D levels. N Engl J Med. 2005 Feb 3;352(5):515-6; author reply 515-6. doi: 10.1056/NEJM200502033520521. No abstract available.
Results Reference
background
PubMed Identifier
21706518
Citation
Hollis BW, Johnson D, Hulsey TC, Ebeling M, Wagner CL. Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness. J Bone Miner Res. 2011 Oct;26(10):2341-57. doi: 10.1002/jbmr.463. Erratum In: J Bone Miner Res. 2011 Dec; 26(12):3001.
Results Reference
result
PubMed Identifier
21857221
Citation
Hollis BW, Wagner CL. Vitamin D requirements and supplementation during pregnancy. Curr Opin Endocrinol Diabetes Obes. 2011 Dec;18(6):371-5. doi: 10.1097/MED.0b013e32834b0040.
Results Reference
result
PubMed Identifier
29046301
Citation
Wei W, Shary JR, Garrett-Mayer E, Anderson B, Forestieri NE, Hollis BW, Wagner CL. Bone mineral density during pregnancy in women participating in a randomized controlled trial of vitamin D supplementation. Am J Clin Nutr. 2017 Dec;106(6):1422-1430. doi: 10.3945/ajcn.116.140459. Epub 2017 Oct 18.
Results Reference
derived

Learn more about this trial

Evaluation of Vitamin D Requirements During Pregnancy

We'll reach out to this number within 24 hrs